This report aims to explore the events and trends of the biopharmaceutical industry in 2024 (YTD December 2024). This year, 22 novel antibody drugs have been approved by at least one regulatory agency around the world.
These drugs range from monoclonal antibodies to bispecifics and antibody-drug conjugates (ADCs). ADCs in particular are extremely exciting as cancer therapies, being projected to surpass USD 50 billion by 2030. What’s more, antibody drug approvals are going global, with the United States remaining at the forefront of antibody drug development, but China quickly catching up.
2024 saw several large collaborations and acquisitions of up to $10 billion in value, primarily for ADCs and multispecifics. The majority of M&A deals worth over USD $1B have been in the first half of 2024. Investment in antibody drug startups focuses heavily on the use of artificial intelligence (AI) and bispecifics for inflammatory and immunology diseases.
Biointron’s Q2 2025 antibody industry report aims to explore the events and tren……
Biointron’s Q1 2025 annual antibody report aims to explore the events and trends……
Sjögren’s disease (SjD) is a chronic, systemic autoimmune disorder characterized……
Immune cell engagers (ICEs) are engineered molecules that redirect endogenous im……
ScientistとScience Exchangeとのご利用可能です。
